In 2020, the development of SARS-CoV-2 vaccines proceeded at a historic pace. Facing many challenges early on – a new disease poorly understood immunity, and an uncertain trajectory of the outbreak – a U.S. government effort brought together many partners to develop and advance several SARS-CoV2 vaccines. The vaccine development model included harmonized trial designs, collaborating clinical trial networks, and collaborating laboratory and statistical efforts. As of February 2021, two mRNA vaccines are being distributed under FDA Emergency Use Authorization (EUA) and several other vaccines are in various stages of clinical testing. Properly interpreting and comparing estimates of efficacy in these trials requires an understanding of the many variables involved and their potential effect on efficacy estimates. This talk will review the framework for the U.S. Covid-19 trials and discuss challenges and lessons learned.